ArticleFunctional & integrative genomics2026
USF1-mediated transcription of PARP1 contributes to sevoflurane-induced pyroptosis in perioperative neurocognitive disorders.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Perioperative neurocognitive disorders (POCD) are a class of common complications of central nervous system after general anesthesia and surgery. Sevoflurane (SEV) is a widely used inhalation anesthetic in clinical practice, but the mechanism of SEV-induced neuronal damage has not yet been fully elucidated. This study aimed to investigate the mechanism of SEV-induced neuronal pyroptosis involving upstream stimulatory factor 1 (USF1) and poly (ADP-ribose) polymerase 1 (PARP1). Single-cell RNA sequencing screening on GSE267933 dataset was performed. POCD animal model was established using C57BL/6J mice, and open field test and Y maze test were conducted to assess cognitive function. Cell model was constructed using human cortical neuronal cell line (CP-H120) and mouse hippocampal neuron cells (HT22). Western blot was employed for protein detection. Cell viability was examined using cell counting kit-8. Pyroptosis was evaluated by enzyme-linked immunosorbent assay, lactate dehydrogenase release assay, flow cytometry, and immunofluorescence staining. The binding between USF1 and PARP1 promoter was analyzed by chromatin immunoprecipitation assay, DNA pull-down assay and dual-luciferase reporter assay. Single-cell sequencing analysis on GSE267933 dataset identified that PARP1 was highly expressed in hippocampal neurons after SEV exposure (P < 0.05). PARP1 knockdown improved cognitive dysfunction and pyroptosis in SEV-exposed POCD mice (P < 0.05). PARP1 downregulation inhibited SEV-induced pyroptosis in human neuronal cells (P < 0.05). USF1 served as a transcription factor to promote PARP1 expression (P < 0.05). Silencing USF1 suppressed SEV-induced pyroptosis in human neuronal cells by downregulating PARP1 (P < 0.05). These findings indicated that USF1-mediated upregulation of PARP1 promoted SEV-induced neuronal pyroptosis, suggesting that USF1/PARP1 axis may function as a key regulator in SEV-triggered neuronal damage in POCD.
Indexed as
Identifiers
42521865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.